2016 Hematological Malignancies

EORTC H8F Clinical Trial FFTF for pts with early favorable HL

100

3-MOPP-ABV + IF (n=270)

80

60

STNI (n=272)

40

20

P <0.001

0

Event-free Survival (%)

0

2

4

6

8

10

Time since Randomization (year)